半岛bd体育手机客户端 说明
一般描述
Increasing drug candidate predictability earlier in the discovery pipeline using non-cell-based assays can improve candidate throughput during the ADME stage. Non-cell-based permeability assays are predictive models for oral absorption of development candidates.
MultiScreen Permeability, MultiScreen-IP, and MultiScreen Acceptor plates support artificial membrane strategies for predicting passive transport.
Membranes have uniform pore structure and density for reliable transport:
- Individual wells minimize candidate cross-talk
- Compatibility with automated liquid handling systems increases throughput
Permeability Assay:
- The MultiScreen Permeability plate has a polycarbonate membrane, which supports a hexane/hexadecane artificial layer for permeability assays.1
PAMPA Assay:
- The MultiScreen-IP plate has a hydrophobic PVDF membrane, which supports a lipid bilayer for PAMPA asays.2,3
MultiScreen Acceptor Plate:
- The MultiScreen Acceptor plate can be used with either plate to capture passively transported compounds. Constructed of 100% PTFE, the plate can improve LC/MS results depending on the charge of the small molecules being evaluated.
应用
Non-Sterile, reusable, sturdy device made of PTFE, acceptor plate for PAMPA assays, 1 plate
Research Category
Nucleic acid|Protein
外形
Color Code:Not Applicable
其他说明
Automation Compatible:Yes
法律信息
MULTISCREEN is a registered trademark of Merck KGaA, Darmstadt, Germany
基本信息
eCl@ss | 32039006 |
半岛bd体育手机客户端 性质
无菌性 | non-sterile |
manufacturer/tradename | MultiScreen® |
technique(s) | parallel artificial membrane permeation assay (PAMPA): suitable |
板尺寸 | 96 wells |
Sigma-Aldrich